<DOC>
	<DOCNO>NCT00409916</DOCNO>
	<brief_summary>The purpose study determine whether outpatient therapeutic management guide impedance cardiography ( ICG ) , addition standard clinical assessment , result long time day first heart failure hospitalization therapy guide clinical assessment alone .</brief_summary>
	<brief_title>PREVENT-HF : Prevention Heart Failure Events With Impedance Cardiography Testing</brief_title>
	<detailed_description>The course patient chronic heart failure mark periodic episode clinical decompensation impair quality life may fatal also consume substantial health care resource , primarily due cost hospitalization . Heart failure management program develop reduce frequency severity clinical event , effectiveness may limit physician ' difficulty identify patient imminent risk . Reliable prediction event may afford physician opportunity intervene aggressively potentially minimize need hospitalization risk serious adverse outcome . Noninvasive impedance cardiography ( ICG ) simple test utilizes change thoracic electrical impedance measure thoracic fluid content , change duration cardiac ejection velocity blood flow within aorta . ICG use estimate cardiac output cardiac filling pressure patient without heart failure ( HF ) . PREVENT-HF randomized prospective study conduct 35 experienced investigative center United States , Canada , Europe . Subjects enrol within 4-12 day discharge hospitalization exacerbation heart failure , screen procedure occur prior enrollment . Following enrollment , subject randomized 1:1 ratio outpatient management either clinical assessment ( Standard Care Arm ) ICG addition clinical assessment ( ICG Arm ) enrollment visit . ICG variable collect subject blind Standard Care Arm . Each subject 's study participation last minimum 24 week maximum 52 week post-discharge . Four week hospital discharge , subject visit clinic . Remaining study visit occur every four week thereafter subject complete 52-week visit subject experience hospitalization adjudicate Clinical Events Committee heart failure hospitalization . In PREDICT study , composite ICG score powerful predictor short-term HF event compare standard clinical variable . This composite ICG score provide subject PREVENT-HF ICG Arm . If score indicate subject high risk short-term HF event , clinician require intervene . Clinicians may intervene indicate subject 's clinical status intermediate-risk score , intervention recommend base ICG score lower-risk score . Compliance guideline track .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Discharge within 12 day hospitalization primary diagnosis heart failure Age 18 year old Chronic heart failure least 2 month ' duration due ischemic nonischemic etiology Receiving medication heart failure consider ( judgment physician ) appropriate clinical status Able acquire data successfully BioZ device Able willing provide write informed consent Height &lt; 48 inch &gt; 90 inch ( &lt; 120 cm &gt; 230 cm ) ; weight &lt; 67 lbs &gt; 341 lb ( &lt; 30 kg &gt; 155 kg ) Acute heart failure due myocarditis , cor pulmonale , congenital heart disease , constrictive pericarditis , hypertrophic , restrictive obstructive cardiomyopathy Presence severe aortic regurgitation Acute coronary syndrome ( myocardial infarction unstable angina ) coronary revascularization procedure ( coronary bypass surgery angioplasty ) within 2 month History resuscitate sudden death , ventricular fibrillation , hemodynamically destabilize VT unless treat properly function ICD One episodes ventricular fibrillation hemodynamically destabilizing ventricular tachycardia within previous 30 day Second degree Mobitz Type II third degree heart block , unless treat cardiac pacemaker Implantation leave ventricular assist device , hemodynamic monitor , activate minute ventilation pacemaker , biventricular pacemaker ( cardiac resynchronization therapy ) VtoV interval set 5 millisecond offset Implantation CRT ( cardiac resynchronization therapy ) device within previous 30 day Planned implantation CRT within next 6 month Clinician use intrathoracic impedance data implant pacemaker capability Participation transtelephonic internetbased formal monitoring program Most recent serum creatinine &gt; 3 mg/dl ; liver function test ( ALT , AST bilirubin ) &gt; 3 time upper limit normal ; chronic dialysis ; chronic ultrafiltration Plan serially monitor Btype natriuretic peptide ( BNP ) Nterminal prohormone Btype natriuretic peptide ( NTproBNP ) part outpatient management Postdischarge management outpatient infusion Pulmonary disease sufficient significantly limit exercise require longterm treatment oral corticosteroid Known hypersensitivity allergy sensor gel adhesive ; skin lesion prohibit adequate sensor placement Women know pregnant planning become pregnant next 12 month Current participation investigational drug device protocol , exception registry subject longterm safety followup active treatment least 60 day Subjects disorder heart failure might expect compromise survival within next 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>heart failure</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>impedance cardiography</keyword>
	<keyword>ICG</keyword>
	<keyword>transthoracic electrical bioimpedance</keyword>
	<keyword>non-invasive</keyword>
	<keyword>TEB</keyword>
</DOC>